These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 7920257)

  • 1. Proteolytic excision and in situ cyclization of a bioactive loop from an REI-VL presentation scaffold.
    Helms LR; Wetzel R
    Protein Sci; 1994 Jul; 3(7):1108-13. PubMed ID: 7920257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strong inhibition of fibrinogen binding to platelet receptor alpha IIb beta 3 by RGD sequences installed into a presentation scaffold.
    Lee G; Chan W; Hurle MR; DesJarlais RL; Watson F; Sathe GM; Wetzel R
    Protein Eng; 1993 Sep; 6(7):745-54. PubMed ID: 8248098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A paradigm for drug discovery using a conformation from the crystal structure of a presentation scaffold.
    Zhao B; Helms LR; DesJarlais RL; Abdel-Meguid SS; Wetzel R
    Nat Struct Biol; 1995 Dec; 2(12):1131-7. PubMed ID: 8846226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of hybrid peptide analogs to receptor recognition domains on alpha- and gamma-chains of human fibrinogen on fibrinogen binding to platelets.
    Mohri H; Ohkubo T
    Thromb Haemost; 1993 May; 69(5):490-5. PubMed ID: 8322271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel cyclization chemistry especially suited for biologically derived, unprotected peptides.
    Wood SJ; Wetzel R
    Int J Pept Protein Res; 1992 Jun; 39(6):533-9. PubMed ID: 1399273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased amyloidogenicity caused by mutational modulation of surface properties of the immunoglobulin light chain BRE variable domain.
    Kobayashi Y; Tsutsumi H; Abe T; Ikeda K; Tashiro Y; Unzai S; Kamikubo H; Kataoka M; Hiroaki H; Hamada D
    Biochemistry; 2014 Aug; 53(31):5162-73. PubMed ID: 25062800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Destabilizing loop swaps in the CDRs of an immunoglobulin VL domain.
    Helms LR; Wetzel R
    Protein Sci; 1995 Oct; 4(10):2073-81. PubMed ID: 8535243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains.
    van den Beucken T; van Neer N; Sablon E; Desmet J; Celis L; Hoogenboom HR; Hufton SE
    J Mol Biol; 2001 Jul; 310(3):591-601. PubMed ID: 11439026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-assembly of cyclic peptides on a dendrimer: multiple cyclic antigen peptides.
    Spetzler JC; Tam JP
    Pept Res; 1996; 9(6):290-6. PubMed ID: 9048422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A discrete sequence in a platelet integrin is involved in ligand recognition.
    D'Souza SE; Ginsberg MH; Matsueda GR; Plow EF
    Nature; 1991 Mar; 350(6313):66-8. PubMed ID: 2002847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. General mutagenesis/gene expression procedure for the construction of variant immunoglobulin domains in Escherichia coli. Production of the Bence-Jones protein REIv via fusion to beta-lactamase.
    Kolmar H; Ferrando E; Hennecke F; Wippler J; Fritz HJ
    J Mol Biol; 1992 Nov; 228(2):359-65. PubMed ID: 1453448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular dynamics simulations of certain RGD-based peptides from Kistrin provide insight into the higher activity of REI-RGD34 protein at higher temperature.
    Upadhyay SK
    Chem Biol Drug Des; 2014 May; 83(5):600-9. PubMed ID: 24877256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressory activity of ubiquitin fragments containing retro-RGD sequence.
    Szewczuk Z; Stefanowicz P; Wilczyński A; Staszewska A; Siemion IZ; Zimecki M; Wieczorek Z
    Biopolymers; 2004 Aug; 74(5):352-62. PubMed ID: 15222015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous platelet fibrinogen surface expression on activated platelets.
    Gralnick HR; Williams S; McKeown L; Connaghan G; Shafer B; Hansmann K; Vail M; Fenton J
    J Lab Clin Med; 1991 Dec; 118(6):604-13. PubMed ID: 1744509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta 3 integrin derived peptide 217-230 inhibits fibrinogen binding and platelet aggregation: significance of RGD sequences and fibrinogen A alpha-chain.
    Lasz EC; McLane MA; Trybulec M; Kowalska MA; Khan S; Budzynski AZ; Niewiarowski S
    Biochem Biophys Res Commun; 1993 Jan; 190(1):118-24. PubMed ID: 8422238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The primary structure of a crystalline monoclonal immunoglobulin kappa-type L-chain, subgroup I (Bence-Jones protein Rei.); isolation and characterization of the tryptic peptides; the complete amino acid sequence of the protein; a contribution to the elucidation of the three-dimensional structure of antibodies, in particular their combining site (author's transl)].
    Palm W; Hilschmann N
    Hoppe Seylers Z Physiol Chem; 1975 Feb; 356(2):167-91. PubMed ID: 809329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclic pentapeptide analogs based on endomorphin-2 structure: cyclization studies using liquid chromatography combined with on-line mass spectrometry and tandem mass spectrometry.
    Piekielna J; Kluczyk A; Perlikowska R; Janecka A
    Peptides; 2014 May; 55():32-40. PubMed ID: 24525024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural relationship of lambda-type light chains with AL amyloidosis.
    Alim MA; Yamaki S; Hossain MS; Takeda K; Yamagata F; Takashi I; Shinoda T
    Clin Immunol; 1999 Mar; 90(3):399-403. PubMed ID: 10075869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of platelet activation by peptide analogs of the beta(3)-intracellular domain of platelet integrin alpha(IIb)beta(3) conjugated to the cell-penetrating peptide Tat(48-60).
    Dimitriou AA; Stathopoulos P; Mitsios JV; Sakarellos-Daitsiotis M; Goudevenos J; Tsikaris V; Tselepis AD
    Platelets; 2009 Dec; 20(8):539-47. PubMed ID: 19863457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences.
    Singer II; Kawka DW; DeMartino JA; Daugherty BL; Elliston KO; Alves K; Bush BL; Cameron PM; Cuca GC; Davies P
    J Immunol; 1993 Apr; 150(7):2844-57. PubMed ID: 8095956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.